Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026
Image
New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.
Ro's platform generates first clinical data on Wegovy pill switch patients
The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.